X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
oncology (60) 60
female (50) 50
cancer (48) 48
index medicus (48) 48
male (47) 47
aged (46) 46
lung neoplasms - drug therapy (46) 46
life sciences (43) 43
carcinoma, non-small-cell lung - drug therapy (38) 38
middle aged (38) 38
lung neoplasms - pathology (37) 37
chemotherapy (36) 36
adult (34) 34
respiratory system (34) 34
carcinoma, non-small-cell lung - pathology (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
lung cancer (28) 28
[ sdv.can ] life sciences [q-bio]/cancer (26) 26
lung neoplasms - mortality (26) 26
prognosis (25) 25
survival (24) 24
neoplasm staging (22) 22
surgery (22) 22
survival rate (22) 22
aged, 80 and over (20) 20
carcinoma, non-small-cell lung - mortality (20) 20
lung neoplasms - surgery (19) 19
mesh : humans (19) 19
carcinoma, non-small-cell lung - surgery (18) 18
deoxycytidine - analogs & derivatives (18) 18
lung neoplasms (18) 18
mesh : lung neoplasms (18) 18
cisplatin (17) 17
non-small cell lung cancer (17) 17
treatment outcome (17) 17
disease-free survival (16) 16
cisplatin - administration & dosage (15) 15
deoxycytidine - administration & dosage (15) 15
lung cancer, non-small cell (15) 15
non-small-cell lung cancer (14) 14
survival analysis (14) 14
lung neoplasms - therapy (13) 13
radiotherapy (13) 13
carcinoma, non-small-cell lung (12) 12
carcinoma, non-small-cell lung - therapy (12) 12
combined modality therapy (12) 12
mesh : carcinoma, non-small-cell lung (12) 12
multivariate analysis (12) 12
open-label (12) 12
carcinoma (11) 11
clinical trials (11) 11
france (11) 11
human health and pathology (11) 11
research (11) 11
carboplatin - administration & dosage (10) 10
care and treatment (10) 10
docetaxel (10) 10
lung neoplasms - diagnosis (10) 10
neoadjuvant therapy (10) 10
preoperative chemotherapy (10) 10
prospective studies (10) 10
pulmonology and respiratory tract (10) 10
quality of life (10) 10
chemotherapy, adjuvant (9) 9
gemcitabine (9) 9
hematology, oncology and palliative medicine (9) 9
mesh : aged (9) 9
mesh : female (9) 9
mesh : male (9) 9
antineoplastic agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
follow-up studies (8) 8
proportional hazards models (8) 8
therapy (8) 8
trial (8) 8
vinblastine - analogs & derivatives (8) 8
[sdv.can]life sciences [q-bio]/cancer (7) 7
carboplatin (7) 7
carcinoma, non-small-cell lung - diagnosis (7) 7
diagnosis (7) 7
france - epidemiology (7) 7
mesh : middle aged (7) 7
mesh : survival rate (7) 7
methodology (7) 7
paclitaxel - administration & dosage (7) 7
patients (7) 7
phase-iii trial (7) 7
risk factors (7) 7
time factors (7) 7
vinblastine - administration & dosage (7) 7
[ sdv.mhep.psr ] life sciences [q-bio]/human health and pathology/pulmonology and respiratory tract (6) 6
adjuvant chemotherapy (6) 6
age factors (6) 6
cancer therapies (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
drug therapy (6) 6
etoposide (6) 6
gefitinib (6) 6
lung neoplasms - genetics (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1619 - 1620
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
Summary Background Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on... 
Hematology, Oncology and Palliative Medicine | DOUBLE-BLIND | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article